Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma [Randomisierte, doppelblinde, Placebo-kontrollierte Phase II-Studie zur Bewertung von Wirksamkeit und Sicherheit einer Behandlung mit Sorafenib bei Patienten mit medullärem Schilddrüsenkarzinom]

Trial Profile

Randomized double-blind placebo controlled Phase II study to evaluate the efficacy and safety of Sorafenib treatment in patients with advanced (recurrent, persistent and/or metastasizing) medullary thyroid carcinoma [Randomisierte, doppelblinde, Placebo-kontrollierte Phase II-Studie zur Bewertung von Wirksamkeit und Sicherheit einer Behandlung mit Sorafenib bei Patienten mit medullärem Schilddrüsenkarzinom]

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Thyroid cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms SUMMIT
  • Most Recent Events

    • 16 May 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 28 Nov 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01736878).
    • 28 Nov 2012 Planned End Date changed from 11 Jan 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top